MYMD VS CNTX Stock Comparison

Performance

MYMD
10/100

MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.

CNTX
66/100

CNTX returned -17.89% in the last 12 months. Based on SPY's performance of -21.29%, its performance is above average giving it a score of 65 of 100.

Technicals

MYMD
25/100

MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

CNTX
21/100

CNTX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Profit

MYMD
10/100

Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.

CNTX
10/100

Out of the last 14 quarters, CNTX has had 2 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MYMD
40/100

MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

CNTX
58/100

CNTX has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

Sentiment

MYMD

"Sentiment" not found for MYMD

CNTX
70/100

CNTX had a bullish sentiment score of 69.84% across Twitter and StockTwits over the last 12 months. It had an average of 27.35 posts, 16.22 comments, and 86.78 likes per day.

Earnings

MYMD

"Earnings" not found for MYMD

CNTX
20/100

CNTX has missed earnings 3 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary

Nasdaq / MYMD

Healthcare

Biotechnology

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Context Therapeutics Inc. Common Stock Summary

Nasdaq / CNTX

Healthcare

Biotechnology

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Power up your portfolio